HTML Sitemap
Pages
- Application Builder
- Case Studies
- Company
- Contact Us
- Cookie Policy
- Device Regulation Library
- Home
- Newsletter
- Privacy Policy
- RegDesk Alerts
- RegDesk Blog
- RegDesk Dash
- RegDesk Peer
- RegDesk Regulatory Consulting
- RegDesk RIMs
- RegDesk Tracking
- Regulatory Intelligence
- Regulatory Intelligence Test
- Who We Serve
- Why Choose Us
Device Regulation Library
- Kuwait Medical Device Regulations
- Oman Medical Device Regulations
- Lebanon Medical Device Regulations
- European Union Medical Device Regulations
- Bangladesh Medical Device Regulations
- Uruguay Medical Device Regulations
- Paraguay Medical Device Regulations
- Canada Medical Device Regulations
- Bahrain Medical Device Regulations
- Jordan Medical Device Regulations
- Nigeria Medical Device Regulations
- Kenya Medical Device Regulations
- Colombia Medical Device Regulations
- Chile Medical Device Regulations
- Phillipines Medical Device Regulations
- Indonesia Medical Device Regulations
- New Zealand Medical Device Regulations
- Australia Medical Device Regulations
- Algeria Medical Device Regulations
- Egypt Medical Device Regulations
- South Africa Medical Device Regulations
- Mexico Medical Device Regulations
- Argentina Medical Device Regulations
- Brazil Medical Device Regulations
- Iran Medical Device Regulations
- Pakistan Medical Device Regulations
- Thailand Medical Device Regulations
- United Arab Emirates Medical Device Regulations
- Saudi Arabia Medical Device Regulations
- Turkey Medical Device Regulations
- Israel Medical Device Regulations
- Singapore Medical Device Regulations
- Vietnam Medical Device Regulations
- Russia Medical Device Regulations
- Taiwan Medical Device Regulations
- Malaysia Medical Device Regulations
- India Medical Device Regulations
- China Medical Device Regulations
- Korea Medical Device Regulations
- Japan Medical Device Regulations
Blog
+Africa
- TMDA Guidance on Changes to Medical Devices: Application Process
- TMDA Guidance on Application For Changes: Software, Materials, and Labeling
- TMDA Guidance on Applications for Changes: Design and Sterilization
- Tanzanian Guidance on Changes to Medical Devices: Un-permissible Changes and Decision Trees
- TMDA Guidance on Changes to Approved Medical Devices: Types of Changes
- TMDA Guidance on Changes to Medical Devices: Overview
- Kenyan Guidance on PMS: Three Steps Approach, Documentation, and Reporting
- Kenyan Guidance on PMS: Procedure and Testing
- Kenyan Guidance on Post-Market Surveillance: Communication
- Kenyan Guidance on Post-marketing Surveillance: Reporting
- Kenyan Guidance on Post-Marketing Surveillance: Roles and Responsibilities
- Kenyan Guidance on Post-marketing Surveillance: Overview
- SAHPRA Guidance on Medical Device Establishment License Renewal
- EDA Guidance on UDI: Import, Distribution, and Delivery
- EDA Guidance on UDI Requirements for Medical Devices: Specific Requirements
- EDA Guidance on UDI Requirements: SaMD and Implantable Devices
- EDA Guidance on Requirements for Unique Device Identification for Medical Devices: Basics
- HSA Guidance on Medical Device Product Registration: Class C and D
- HSA Guidance on Medical Device Registration: Basics
- EFDA Guidance on Medical Device Bundling
- Tanzanian Draft Regulation on Laboratory Analysis
- EFDA Guidance on Post-Approval Change Notification
- EFDA Guidelines on Low-Risk Medical Devices
- NDDA Notice on Sample Collection Rules for Medical Devices
- Tanzania on Storage and Distribution of Medical Devices
- Change Control: Ethiopian Guidance for Medical Devices
- ISO Considers Rewriting Their ISO 13485:2016 Standard
- ICMRA Looking to Collaborate with Experts on Track and Trace
- #1 Mistake To Avoid When Registering Your Device Abroad
- How to Come Back from a Denied Product Registration Application
- Multi-Sourcing Intelligence: The Ticket to Regulatory Success
- What You Need to Know About UDI’s
- Tragic Origins of the International Conference on Harmonisation (ICH) and Our Modern FDA
- 5 Tips for Sending your Product to a Emerging Market of Medical Device
- Get to Know: MENA Regulations Authorities
+Asia
- NHRA Draft Guidance on Online Medical Devices Importation Approval: Overview
- MDA Guidance on Combination Products: Timelines, Fees, and Changes
- MDA Guidance on Combination Products: Registration Process
- DRAP Guidance on Reliance Mechanism in Regulatory Processes: Overview
- MDA Guidance on Combination Products: Overview
- NHRA Guidance on Medical Devices Registration: Variations
- NHRA Guidance on Medical Device Registration: Overview
- HSA Guidance on Adverse Events Reporting: Details
- HSA Guidance on Reclassification: Medical Devices to be Introduced Into the Body
- HSA Guidance on Adverse Events Reporting: IVDs and Timelines
- HSA Guidance on the Reporting of Adverse Events: Overview
- HSA Guidance on Medical Device Advertisements and Sales Promotion: Specific Rules and Corrective Measures
- HSA Guidance on Advertising and Promotion: General Principles
- HSA Guidance on Medical Device Advertisements and Sales Promotion: Overview
- HSA Guidance on Importation of Unregistered Medical Devices for Exhibition: Specific Aspects
- HSA Guidance on Importation of Unregistered Devices for Exhibition: Overview
- HSA Guidance on Cancellation of a Medical Device: Overview
- HSA Guidance on Change of Registrant: Overview
- HSA Guidance on Change Notification for EU MDR/IVDR Related Changes
- HSA Guidance on Change Notifications: Implementation Process
- HSA Guidance on Change Notification: Application Process
- HSA Guidance on Change Notification: Change Type Flowcharts
- HSA Guidance on Change Notification: FSCA-related Changes and Exemptions
- HSA Guidance on Change Notification: Categories of Changes
- HSA Guidance on Change Notification: Overview
- HSA Guidance on GDP: Internal Audits and Outsourcing
- HSA Guidance on GDP: Counterfeit Devices and Complaint Handling
- HSA Guidance on GDP: Good Assembly Practice and Traceability
- HSA Guidance on SAR: Post-Market Obligations and Summary
- HSA Guidance on Standard GDP: Key Principles of Secondary Assembly
- HSA Guidance on Special Access Routes: Requirements
- HSA Guidance on Good Distribution Practice: Delivery, Installation, and Servicing
- HSA Guidance on Special Access Routes: Overview
- HSA Guidance on GDP: Storage Conditions and Principles
- HSA Guidance on Good Distribution Practice: Overview
- HSA Guidance on UDI System: Implementation Timeline
- HSA Guidance on UDI System: Information Submission Details and Device-specific Rules
- HSA Guidance on UDI System: New e-service and Change Notification
- HSA Guidance on UDI System: UDI Development and Placement
- HSA Guidance on UDI System: Components and Labeling
- New HSA Guidance on UDI: Overview
- HSA Guidance for Dealers on Class A Medical Devices: Overview
- HSA Guidance on Establishment Licenses: Renewal, Suspension, and Inspections
- HSA Guidance on Establishment Licenses: Changes to Dealer’s License Information
- DRAP Guidance on Clinical Trials Applications: Documents
- NHRA Guidance on Medical Device Importation Approval: General Rules and Specific Aspects
- HSA Guidance on Establishment Licensing: Overview
- DRAP Guidance on Clinical Trials: Registries and Investigator’s Brochure
- HSA Guidance on Establishment Licensing: Overview
- DRAP Guidance on Clinical Trials Applications: CGP Compliance Audits and Reports
- HSA Guidance on Essential Principles: Supply-Related Risks, Combination Products, and IVDs
- HSA Guidance on Essential Principles: Radiation, Lay Persons, Biological Materials
- DRAP Guidance on Clinical Trials: Import, Timelines, and Ethical Approval
- HSA Guidance on Essential Principles: Device-Specific Principles and Risks
- DRAP Guidance on Clinical Trials: Application in Detail
- HSA Guidance on Essential Principles: Sterility and Use Environment
- DRAP Guidance on Clinical Trials Applications: Overview
- HSA Guidance on Essential Principles: General Provisions and Clinical Trials
- HSA Guidance on Essential Principles: Standards and Applicability
- HSA Guidance on Essential Principles: Overview
- NHRA Guidance on Medical Device Importation Approval: Overview
- HSA Guidance on Change Notification: Specific Aspects
- HSA Guidance on Change Notification Requirements: Application Process
- HSA Guidance on Change Notification: Overview
- HSA Guidance on Declaration of Conformity
- Turkish Regulation on Clinical Trials: Specific Aspects
- HSA Guidance on Clinical Evaluation: Analysis of the Clinical Data
- Turkish Regulation on Clinical Trials: Reports and Responsibilities
- HSA Guidance on Clinical Evaluation: Data Types and Appraisal
- DRAP Guidance on Imports & Exports of Therapeutic Goods: Overview
- HSA Guidance on Data Sources for Clinical Evaluation: Literature Review
- HSA Guidance on Clinical Evaluation: General Principles
- HSA Guidance on Clinical Evaluation: Overview
- HSA Guidance on Grouping of Medical Devices: Grouping Categories
- HSA Guidance on Grouping of Medical Devices: Overview
- HSA Guidance on IVD Classification
- HSA Guidance on Labeling for Medical Devices: Implantable Devices and IVDs
- HSA Guidance on Labeling: Content of Labeling
- Turkish Regulation on Clinical Trials: Responsibilities of the Parties
- Turkish Draft Regulation on Clinical Trials: Basics
- HSA Guidance on Labeling for Medical Devices: Introduction
- Circular on Renewal of Medical Device Licenses – Jordan
- HSA Guidance on Product Registration Submissions: ASEAN CSDT in Detail
- HSA Guidance on Preparation of a Product Registration Submission: Overview
- New Turkish Regulation on Quality Compliance and Control Tests
- HSA FAQ on 3D-Printed Medical Devices: Basics
- HSA Guidance on Telehealth Products: Classification and Regulatory Controls
- HSA Guidance on Telehealth Products: Basics
- HSA Guidance on Risk Classification of General Medical Devices: Classification Rules in Detail
- PADC Guidance on Registration of High-Risk Medical Devices: Annexes
- HSA Guidance on Classification of General Medical Devices: General Principles
- HSA Guidance on a Life Cycle Approach for AI-based Medical Devices: Specifics, Post-market Monitoring and Changes
- HSA Guidance on Life Cycle Approach for AI-based Devices: Regulatory Basics
- HSA Guidance on Life Cycle Approach for Software Medical Devices: Cybersecurity
- HSA Guidance on Post-Market Management of Software Medical Devices
- HSA Guidance on Life Cycle Approach for Software Medical Devices: Activity Controls and Change Notification
- HSA Guidance on Software Medical Devices: Pre-Market Product Registration Requirements
- HSA Guidance on Software Medical Devices: Basics
- HSA Guidance on 3D-printed Medical Devices
- Oman Guidance on Medical Devices Bundling / Grouping Criteria
- HSA Guidance on IVD Analyzers: SMDR Listing Options
- Oman Guidance on Fast Track High-Risk Medical Devices Registration
- HSA Guidance on IVD Analyzers
- HSA Guidance on Medical Device Advertisements
- HSA Guidance on Medical Device Product Registration: Additional Aspects
- HSA Guidance on Medical Device Advertisement: Basics
- HSA Draft Guidance on Qualification of CDSS
- HSA Consultation on Risk Classification of Standalone Medical Mobile Applications (SaMD)
- HSA Guidance on UDI Implementation Process
- HSA Guidance on Medical Device Unique Device Identification System
- Philippines on Licensing Inspection for Radiation Facilities
- HSA Announces Singapore’s UDI System
- Thailand FDA on Direct Advertising and Labeling
- Taiwan on Registration of Single-Use Medical Devices
- MDA Guidance on Conformity Assessment Body Registration
- Taiwan on Medical Device Safety Monitoring and Surveillance
- Taiwan Draft Guidance on Adverse Event Reporting
- FDA on Water-Circulating Hot/Cold Therapy Devices
- MDA on Requirements for Conformity Assessment Bodies
- MDA on Complaint Handling and Problem Reporting
- MDA Guidance on Field Corrective Action
- PMDA on Cybersecurity Assurance of Medical Devices
- An Overview of South Korea and Their Medical Devices
- Japan Issues Updated Guidance on Biocompatibility Testing
- Japan Amends Medical Device Regulations
- Philippines New Medical Device Regulation Framework
- MFDS New Guidance on Imported and Scarce Medical Devices
- Classification Guidelines for Medical Devices in Bangladesh
- Vietnam Amends Medical Device Regulations – 2019
- MFDS Amended Submission Requirements
- MDA Malaysia’s Guidance on Combination Products
- CDSCO Designates Six Bodies To Perform Manufacturing Site Audits
- Saudi Prepares to Improvise Their Medical Devices Regulation
- Turkey Updates Its Medical Device Regulations
- Medical Device Reimbursement in Japan
- An Overview of Medical Device Regulations in Japan
- Meet this Month’s #WebinarWednesday Speaker: Yoojin Ahn
- Our Guide for How to Register Medical Devices in India
- An Overview of Medical Device Regulations in China
- Philippines FDA Has New Medical Device Regulations in the Pipeline
- MHRA Begins Sharing Intelligence with India to Halt Unlicensed Drug Imports
- India CDSCO Transitions to Online Portal for Blood Products
- Chinese CFDA Adds More Devices Exempt from Clinical Trials
- Saudi Arabia Issues Final Guidance on Medical Device National Registry Route
- India to Authenticate Drugs from Top 300 Pharmaceutical Companies
- #WebinarWednesday Sneak Peek: Medical Device Regulations in Pakistan
- What You Need to Know About Pakistan’s New Medical Device Regulations
- Singapore’s HSA Enhances Legislation to Facilitate Faster Access to Medical Devices
- Malaysian Medical Device Regulations to go into Effect July 1
- India’s CDSCO Plans to Regulate High-End Medical Equipment and Implantable Devices
- Regulatory Roundup from Bahrain
- Answers to Your Most Critical IVD Questions for India
- How Could Changing Manufacturing Facilities Impact Your Device Company?
- China’s CFDA Issues Record Keeping Requirements for Clinical Trial Institutions
- Is There an Pathway for Our Combination Device regulations in Korea, India, Taiwan, and China?
- 4 Things You Need to Know About India’s Notified Bodies
- India’s New Medical Device Regulations: 10 Things You Need to Know
- CFDA Seeks to Streamline Regulations to Align with Other Regulatory Bodies
- CFDA Promises to Accelerate Some Drug Approvals
- Things You Need to Know Before Doing Medical Device Business in Japan
- China Priority Review Option Now Available for Medical Devices
- Quick Primer of the New Device Regulations in India
- Perceived Inconsistency in the Requirements of Clinical Data in Japan
- Medical Device Registration Process in Vietnam
- China’s Solution to Shortage of Vaccines
- New CFDA Regulations on Device Clinical Trials
- CFDA Publishes New Medical Device Naming Rule
- China to Stop Drug Operation for Pharma Companies that Don’t Pass New GSP
- Get to Know: South Asia Regulatory Authorities
- Get to Know: East Asia Regulatory Authorities
- List of Recognized Medical Device Standards Issued By Hong Kong
- Global Medical Device Regulations 101
- How to Register Your Medical Device in India
+Australia and Oceania
- TGA on Reclassification of Medical Devices that Administer Medicines
- TGA Guidance on Reclassification of Medical Devices in Direct Contact with the Heart, CCS, and CNS
- TGA Guidance on Reclassification of AIMD for Therapy with a Diagnostic Function
- TGA Guidance on AIMD Reclassification: Notification Process
- TGA Guidance on Reclassification of Active Implantable Medical Devices: Overview
- FDA Guidance on Post-Approval Studies: Reports Format and Content
- FDA Guidance on Clinical Outcome Studies: Specific Aspects
- FDA Guidance on Post-Approval Studies: Reporting in Brief
- FDA Guidance on Post-Approval Studies: Study Protocols
- FDA Guidance on Deficiencies and the Least Burdensome Approach: Deficiency Letters
- FDA Guidance on Handling Post-Approval Studies: Overview
- FDA Guidance on Deficiencies and the Least Burdensome Provisions: Main Principles
- FDA Guidance on Developing and Responding to Deficiencies: Overview
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Non-Comparative Clinical Outcome Studies
- TGA Guidance on Clinical Evidence for Supportive Devices
- TGA Guidance on Clinical Evidence for Heart Valve Replacements: Overview
- TGA Guidance on Clinical Evidence for Implantable Pulse Generator Systems: Overview
- TGA Guidance on Clinical Evidence for Cardiovascular Devices: Specific Aspects
- TGA Guidance on Clinical Evidence for Cardiovascular Devices: Overview
- TGA Guidance on Clinical Evidence for Joint Prostheses: Post-Market Data
- TGA Guidance on Clinical Evidence for Joint Prostheses: Clinical Investigations
- TGA Guidance on Clinical Evidence for Joint Prostheses: Overview
- TGA Guidance on Clinical Evidence: AIMD and PIMD
- TGA Guidance on Clinical Evidence: General MRI Considerations
- TGA Guidance on Clinical Evidence: Comparable Devices in Detail
- TGA Guidance on Clinical Evidence: Comparable Devices
- TGA Guidance on Clinical Evaluation Report: Overview
- TGA Guidance on Clinical Evidence: Considerations for Custom-Made Devices and Additional Aspects
- TGA Guidance on Clinical Evidence: Considerations for Adaptable Medical Devices
- TGA Guidance on Clinical Evidence for Patient-Matched Devices: Specific Aspects
- TGA Guidance on Clinical Evidence: Design Envelope for Patient-Matched Devices
- TGA Guidelines on Clinical Evidence for Personalized Devices: Overview
- MDA Guidance on Re-registration of Medical Devices
- TGA FAQ on Software-based Medical Devices
- TGA Guidance on Applications for Non-Compliant Devices: Application Form
- TGA Guidance on Non-compliant Devices: Basics
- TGA Guidance on Regulated and Unregulated Software: Examples of Regulated Software
- TGA Guidance on Medical Device Incident Reporting: Basics
- TGA Examples of Regulated and Unregulated Software
- TGA Guidance on Surgical Mesh Devices: Preliminary Assessment
- TGA Guidance on Classification of Active Medical Devices: Basics
- TGA Guidance on COVID-related Software: Specific Aspects
- TGA Guidance on Requirements for COVID-related IVDs
- TGA on Regulatory Changes: Software Recommending Treatment
- TGA Guidance on Medical Device Production Systems (MDPS)
- TGA Updates Guidance on Personalized Medical Devices
- TGA on Refinements to the Personalized Medical Devices Framework
- TGA on Regulatory Changes for Software-Based Medical Devices
- TGA Guidance on Implant Cards
- TGA Guidance on Patient Information Leaflets
- TGA Guidance on Medical Software
- TGA Consultation Paper on Medical Devices Applied to the Skin
- TGA Guide on Post Market Review Compliance Dashboard
- TGA on Medical Device Incident Reporting System
- TGA Guidance on Inclusion Process: Application Types
- TGA Guidance on ARTG Registration Step by Step
- TGA Notice on Custom-Made Medical Devices
- TGA: New Australian Framework for Personalized Medical Devices
- TGA Consultation on Regulation of Personalized Medical Devices – Further Details
- TGA Consultation Paper on Proposed Improvements to the Therapeutic Goods Advertising Code
- TGA Consultation on Amendments to Regulation of Personalized Medical Devices
- TGA on Conformity Assessment Bodies
- TGA Guidance on Reclassification of AIMD
- TGA Guidance on Certificates of Free Sale and Export Certificates
- TGA Guidelines on Inclusion Process for Medical Devices (Including IVD)
- TGA Declaration of Conformity for Class I Medical Devices
- TGA on Reclassification of Medicine Delivering Medical Device
- TGA Guidance on Auditing of Medical Device Applications
- TGA Guidance on Supporting Documentation
- TGA on Reclassification of Medical Devices
- TGA: New Details on Clinical Decision Support Software
- TGA Guidance on Clinical Evidence
- TGA Guidance on Seasonal Influenza IVD Self-Tests
- TGA Guidance on Foreign Market Authorization Evidence
- TGA Medical Devices Essential Principles Checklist
- Australian Regulatory Framework on Cybersecurity for Medical Devices
- TGA Consultation on Nanomaterials in Medical Devices
- TGA Guidance on Risk Management Approach
- TGA Guidance on Clinical Decision Support Software
- TGA on Essential Principles for Medical Devices
- MDA Draft Guidance on Medical Device Grouping
- TGA Guidance on Personalized Medical Devices: In-Depth Review
- TGA Guidelines on Personal Protective Equipment
- TGA Guidelines on Sponsorship
- TGA Guidance on Medical Masks and Respirators
- TGA on Post-Market Monitoring and Surveillance of Medical Devices
- TGA Priority Applicant Guidelines for Medical Devices
- TGA on Delays in Conformity Assessment Recertification
- TGA on the Australian Unique Device Identification System
- TGA Consultation on Medical Device Adverse Event Reporting
- Australian Regulatory Guidelines for Medical Devices
- TGA Guidance on 3-D Printing of Medical Devices
- TGA Guidance on Thermal Imaging Systems
- TGA Literature Review of Medical Software Safety Issues
- TGA on Annual Charges Reduction
- TGA on Changes to Implementation Delay
- TGA Summary on Medical Software Consultations
- TGA on Assessment of COVID-19 Tests
- TGA Framework for COVID-19 Tests
- Australia’s TGA Guidance on Thermometers
- TGA Consultation on Software Based Products
- TGA Guidance on Ventilators for COVID-19 in Australia
- Personalised Medical Devices: TGA Regulation Overview
- TGA Guidance on Considerations for Medical Devices
- TGA Consultation Paper on Fees and Charges
- Australia’s Amendments to Medical Device Regulations
- TGA Guidance on IVD Companion Diagnostics
- Overview of Australia’s Therapeutic Goods Administration
- The TGA issues an Update to the Medical Device Regulations
- Updated Australian IMD Registration
- Step-by-Step Guide for How to Register Your Medical Device in Australia
- TGA Proposes Restriction on Pediatric Anesthetic
- Australia’s TGA Delays Implementation of Regulatory Changes for 3D-Printed Devices
- New Online Form for Australian Clinical Trial Notification Scheme
- Medsafe Changes Definitions of Medicines and Medical Devices
+Brazil
- ANVISA Guidance on SaMD: Various Use Examples
- ANVISA Guidance on SaMD: Data Processing Solutions
- ANVISA Guidance on SaMD: ECG Products and Systems
- ANVISA Guidance on SaMD: Various Supply Types
- ANVISA Guidance on SaMD: Remote Diagnosing and Administrative Software
- ANVISA Guidance on SaMD: Telemedicine
- ANVISA Guidance on SaMD: Language and Responsibilities
- ANVISA Guidance on Software as a Medical Device: Evidence and Regulatory Status
- ANVISA Guidance on Software as a Medical Device: Overview
- ANVISA Guidance on Cybersecurity for Medical Devices
- Brazil’s New Rules for Class II Medical Devices
- Brazilian Regulation on Medical Software
- ANVISA: Brazil Implements Special Regulatory Framework
+Canada
- Health Canada Guidance on Clinical Evidence: Comparator Devices
- Health Canada Guidance on Clinical Evidence: Amendments
- Health Canada Guidance on Clinical Evidence: Submission
- Health Canada Guidance on Clinical Evidence Requirements: Overview
- Consultation on Changes to Canadian Medical Device Regulations
- Health Canada Guidance on Investigation of Reported Medical Device Incidents: Closure and Additional Details
- Health Canada Guidance on Investigation of Reported Medical Device Problems: Corrective Actions
- Health Canada Guidance on Investigation of Reported Medical Device Problems: Risk Evaluation and Control
- Health Canada Guidance on Problem Report Investigation: Evaluation, Reporting, and Root Cause Investigation
- Health Canada Guidance on Problem Report Investigation: Collecting Information
- Health Canada Guidance on Recalls: Notification and Corrections
- Health Canada Guidance on Recalls: Reporting Process
- Health Canada Guidance on Problem Investigation Procedure
- Health Canada Guidance on Recall Process: Initiating a Recall
- Health Canada Guidance on Ultrasound Systems: Labeling and Quality System Certification
- Health Canada Guidance on Ultrasound Devices: Application Content in Detail
- Health Canada on Incident Reporting: Submission Content and Specific Aspects
- Health Canada on Significant Changes: Guidance for Implementation
- Health Canada Q&A on License Application Types
- Health Canada Notice on Interpretation of Significant Changes
- Health Canada Guidance on License Application Types
- Health Canada Guidance on Recalls: Basics
- Health Canada: Device Licenses for Ultrasonic Diagnostic Systems and Transducers
- Health Canada Guidance on Risk Management for Medical Devices
- Recent Changes to Medical Device Regulations in Canada
- Health Canada Guidance on Private Label Medical Devices
- Health Canada Guidance on IVDD Classification: Special Rules
- Health Canada on Incident Reporting: Timelines and Content
- Health Canada Guidance on Inspections: Advertising, Labelling, and Manufacturing
- Health Canada IVDD Classification Rules Regarding Transmissible Agents
- Health Canada Guidance on MDEL: Annual Review, Updating, Cancellation, and Suspension
- Health Canada Guidance on Classification of IVDDs
- Health Canada Guidance on Inspections of Medical Device Establishments
- Health Canada Guidance on Applying for an MDEL
- Health Canada on Classification of Non-IVD Medical Devices
- Health Canada on Medical Device Establishment Licensing
- Health Canada on Medical Device Shortages
- Health Canada Framework for COVID-related Medical Devices
- Health Canada Guidance on Issue-Related Analyses for Medical Devices
- Health Canada Guidance on Summary Reports
- Health Canada Guidance on Incident Reporting
- Health Canada: Applications for Medical Devices under the Interim Order
- Health Canada Notice on Interim Orders
- Health Canada Notice on UV Decontamination Devices
- FDA Program on Inspections of Combination Products
- Health Canada announces REP Expansion
- Health Canada Guidance on IO Applications
- Health Canada Guidance on Medical Devices
- Health Canada Guidance for Private Label Medical Devices
+Case Study
- FDA Proposes Major Changes to De Novo Pathway
- WHO and FDA Pilot Initiative to Expedite HIV Drug Applications
- FDA to Overhaul 510(k) Device Approval Process
- National Evaluation System for Health Technology (NEST)
- Regulatory Gap Analysis of Centrally Authorized Biologics in the European Union
- How Would Changing Our Distributor Impact the Sale of Our Medical Devices in Taiwan?
- Assessment of Why Japan’s PMDA May Request Clinical Trial Data Instead of Clinical Evaluation Data
- Why Did My Device Registration Application Get Rejected in Brazil?
- Remediation from Distributor Fiasco
- Gap Analysis of Centrally Authorized Drugs in EU
- Case Study – Labeling Review
- 4 Factors Slowing US Approval of Biosimilars and the Future of the Biosimilar Market
- FDA Clears a Material Enabling 3D-Printing of Dentures
- Open FDA Initiative
- STED Explained
+COVID-19
- FDA Draft Guidance on PBM Devices: Modifications, Definitions, and Labeling
- FDA Draft Guidance on PBM Devices: Clinical Trials – Specific Aspects
- FDA Draft Guidance on PBM Devices: Clinical Trials Overview
- FDA Revised Guidance on COVID-19 Tests: Modifications
- FDA Draft Guidance on Photobiomodulation Devices: Overview
- FDA Revised Guidance on COVID-19 Tests: Laboratory-Developed Tests and Tests Under Review
- EC Proposes New In Vitro Diagnostic Medical Devices Regulation
- Saudi Arabia SFDA Guidance on UDI Requirements
- Peru Adopts Regulation on COVID-19 Tests
- FDA Warning on Protective Barrier Enclosures
- FDA Guidance on Multiple Function Device Products
- FDA Template for At-Home and OTC Diagnostic Tests
- FDA Enforcement Policy for Viral Transport Media
- Danish Guidance on Clinical Trials During the Pandemic
- EC: Conformity Assessment of COVID-related Devices
- MHRA Guidance on COVID-related Medical Devices
- FDA Updated Guidance on COVID-19 Tests
- FDA on Decontamination and Bioburden Reduction Systems
- FDA: Meetings and User Fee Applications for Medical Devices
- FDA: Adverse Event Reporting for EUA Medical Devices
- WHO Notice on COVID-related Issues
- FDA Enforcement Policy for ECMO Devices
- MDCG Guidance During COVID-19 Pandemic
- EC Guidance on Medical Devices in the COVID-19 Context
- MHRA Regulatory Flexibilities and COVID-19 Response
- COVID-19: EC Recommendations and Assessment
+Ethiopia
- EFDA Guidance on GMP Site Inspection Management: Reports and Administrative Measures
- EFDA Guidance on GMP: Competencies and Responsibilities
- EFDA Guidance on GMP Site Inspection Management: Key Points
- EFDA Guidance on Medical Device Labeling: Special Requirements
- EFDA Guidance on Medical Device Labeling: Location and Content
- EFDA Guidance on Medical Device Labeling: Overview
- EFDA Guidelines on Marketing Authorization: Requirements for Virtual Manufacturers
- EFDA Guidelines on Marketing Authorization: Post Approval
- EFDA Guidelines on Marketing Authorization: Exemptions and Application Review
- EFDA Guidance on Application Pathways: Documents and Procedures
- EFDA Guidelines on Submission Pathways and Requirements: General Principles and Requirements
- EFDA Guidelines on Conformity Assessment of Medical Devices: Documentation
- EFDA Guidelines on Conformity Assessment: QMS and Post-Market Surveillance
- EFDA Guidelines for Marketing Authorization of Medical Devices: Classification and Grouping, Borderline Products
- EFDA Guidance on Storage and Distribution: Dispatch and Outsourced Activities
- EFDA Guidance on Storage and Distribution: Personnel, Stock Control, and Other Activities
- EFDA Guidance on Storage and Distribution: Premises
- EFDA Guidance on Good Storage and Distribution Practice: Recalls
- EFDA Guidelines for Marketing Authorization of Medical Devices: Overview
- EFDA Guidance on Clearance: Importation in Detail
- EFDA Guidance on Storage and Distribution: Management Review, Complaints, and Returned Devices
- EFDA Guidance on Requirements of Medical Devices Clearance: Introduction
- EFDA Guidelines Storage and Distribution: Quality Assurance
- EFDA Guidelines on Storage and Distribution: Introduction
+EU MDR/IVDR
- EU MDR transitional period extension: More time to certify medical devices
- Swissmedic FAQ on Medical Device Notifications
- MDCG Guidance on Legacy Devices Under the MDR: Non-Conformity and Timelines
- MDCG Position Paper on Application of Article 97 MDR to Legacy Devices: Overview
- MDCG Guidance on Authorized Representatives: Changes, Responsible Persons and Surveillance
- MDCG Guidance on Authorized Representatives: Responsibilities, Liability, and Termination
- MDCG Guidance on Authorized Representatives: Key Responsibilities
- MDCG Manual on Borderline Products: Key Principles in Detail
- EU Manual on Borderline and Classification for Medical Devices: Overview
- MDCG Position Paper on Notified Bodies
- MDCG Guidance on CABs and NBs: Re-assessment
- MDCG Guidance on CABs and NBs: Notification and Publication
- MDCG Guidance on CABs and NBs: Decision on Designation
- MDCG Guidance on CABs and NBs: Post On-Site Assessment Activities
- MDCG Guidance on CABs and NBs: On-site Assessment Activities
- MDCG Guidance on CABs and NBs: Application Review and Transmission
- MDCG Guidance on Conformity Assessment Bodies and Notified Bodies: Application Pre-assessment
- MDCG Guidance on Alternative Solutions for IVDs: Overview
- MDCG Guidance on Surveillance Under Transitional Provisions: Specific Aspects
- MDCG Guidance on Surveillance Under Transitional Provisions: Overview
- MDCG Q&A on Repackaging and Relabeling Activities
- MDCG Guidance on Classification of Medical Devices: Application and Interpretation
- MDCG on Classification of Medical Devices: Terms and Concepts
- MDCG Guidance on Classification of Medical Devices: Basics
- MDCG Guidance on Certification Activities
- SwissMedic Guidance on Obligations of Authorized Representatives, Importers and Distributors
- EMA Guidance on Quality Documentation: Co-packaged Products
- MDCG Guidance on Performance Evaluation of COVID Tests
- EMA Guidance on Medicines Used in Medical Devices
- MDCG Guidance on UDI Integration: Additional Aspects
- EMA Guidance on Documentation for Medicines in Medical Devices
- MDCG Explanatory Note on IVDR Codes
- MDCG Guidance on UDI Integration
- MDCG Joint Implementation Plan for IVDR
- MDCG Guidance: Registration of ‘Other Actors’ in EUDAMED
- MDCG FAQ on the European Medical Device Nomenclature
- MDCG Publishes IVDR Implementation Plan
- Notified Bodies Assessment Procedures Under MDR/IVDR
- MDR and IVDR: Everything You Need to Know
- EC Proposes New AI Medical Device Regulations
- MDCG Q&A Document on Clinical Investigation
- MDCG Guidance on Standardization for Medical Devices
- MDCG Guidance on Certification of Class D IVDs
- Swissmedic on Changes to Medical Device Regulations in Switzerland
- MDCG Guidance on COVID-19 Rapid Antibody Tests
- FDA Guidance on Medical Device Accessories Classification
- MDCG Q&A Document on Custom-Made Medical Devices
- MDCG Visual Guide to Medical Device Software
- HPRA Guidance on Wholesale Distribution Authorizations
- EC Q&A Document on COVID-19 Tests
- UK Final Revision of Medical Devices Regulations
- EC on Management of Legacy Devices
- MHRA on Health Institution Exemption for Northern Ireland
- NBOG on Designation and Notification of Conformity Assessment Bodies
- NBOG Best Practice Guide on Designation and Notification of Conformity Assessment Bodies
- EC Announces the Launch of Actor Registration Module
- MHRA Guidance on Notifying About Clinical Investigation
- Northern Ireland Medical Device Regulation After Brexit
- Peru: Guidelines on COVID-related Medical Devices Validation
- MDCG Post-market Clinical Follow-Up (PMCF)
- MHRA New Medical Device Regulations
- MDGC QA Document on Protective Equipment
- EC Regulation on Single-Use Devices Reprocessing
- EC on the Unique Device Identification System
- MDCG on Person Responsible for Regulatory Compliance
- MDCG on MDSAP Audit Reports and Surveillance Audits
- MDCG Guidance for Class I Medical Device Manufacturers
- IFU for Reusable and Re-sterilizable Devices
- EC Decision on Standardization for Medical Devices
- MDCG on Medical Devices Containing Ancillary Substances
- MDCG Guidance on Safety Reporting in Clinical Investigations
- EU-wide Derogations: Official EC Guidelines
- EC Amends Notified Bodies Designation Procedure
- EU Council Proposal on Regulation Implementation Dates
- Implant Cards: Further MDCG Guidance
- UDI and Changes to UDI’s: MDCG Guidance
- Explanatory Notes to the UK Medical Devices Bill
- Norway Warns on EUDAMED Delay
- MHRA Guidance For Products Without an Intended Medical Purpose
- MedTech Europe Warns on MDR Implementation Issues
- European Commission has Announced New Nomenclature
- Notified Bodies and Conformity Assessment in the EU
- MDCG Issues Guidance On Class I Medical Devices
- AEMPS Provides Additional Time to Change Labels
- Slovenia Implements New Packaging Requirements
- European Council Published Draft of Second Corrigendum to MDR 745
- Eudamed Database Implementation Date Reportedly Delayed
- EC MDCG Issued Guidance in Qualification and Classification of Software Under the MDR/IVDR
- EC Clarifies Status of Expert Panels
- MHRA Guidance about No-Deal Brexit
- DKMA Consultations on MDR
- CE Certificate Renewal Deadline is Approaching
- EU Medical Device Regulations
- AEMPS Applies for NB Designation
- EMA Releases Guidances Addressing Drug Shortages
- EC issued two additional medical device regulation guidances
- MedTech Published a Detailed Plan Regarding MDR/IVDR
- European Commission Warns About Possible Availability Issues
- An Overview Of Medical Device Regulations In Finland
- New Responsibilities for Manufacturers with the new EU MDR
- Spinal Classification under the New EU MDR: Who will Adopt it?
- The Lowdown on Medical Device Regulations in Estonia
- Overview of Medical Device Regulations in Denmark
- Important Things to Know Before Registering your Medical Device in Czech Republic
- An Overview of Medical Device Regulations in the UK
- BSI Warns Device Manufacturers of ‘No-Deal’ Brexit Scenario
- The US and EU Collaborate on UDI Specifications
- The Lowdown on Medical Device Regulations in Sweden
- BSI UK Named First Notified Body Under EU MDR
- Things You Should Know Before Registering Your Medical Devices in Spain
- 6 Major Differences Between EU’s MDR/IVDR and MDD/IVDD
- India’s CDSCO amends Medical Devices Rules to put IVDs on the fast track
- Do Your Labels Comply with the E.U.’s MDR?
- Implementation Timelines for EU MDR and IVDR
- Quick Overview of the EU’s New Medical Device & EU IVD Regulations
+Europe
- MHRA Guidance on SaMD: Qualification and Concepts
- MHRA Guidance on Software and AI as a Medical Device: Overview
- New Italian Rules for Surgical Masks
- Swissmedic Guidance on Procurement of Medical Devices: Specific Aspects
- EC Implementing Decisions on Harmonized Standards for MDR and IVDR
- Czech Regulation on Advertising: Specific Rules
- Czech Instruction on Advertising Rules for Medical Devices: General Rules
- MHRA Consultation on the Future Regulation of Medical Devices in the UK
- MHRA Guidance on Temperature Screening Equipment
- Offenses and Liability Under the Medicines and Medical Devices Act 2021
- Legislation Overview: UK Medicines and Medical Devices Act 2021
- Changes to the Swiss Medical Device Regulation
- Recent Regulatory Changes for Medical Devices in Eurasia
- Bosnia and Herzegovina’s Medical Devices Info System: Part II
- Guide to Bosnia and Herzegovina’s Medical Device Information System
- Kazakhstan: New Importation and Exportation Rules
- MedTech Europe Position Paper on Virtual Audits
- Swiss Authorizations for Non-Conforming Medical Devices
- MHRA Response to the IMMDS Review
- Swissmedic Guidance on eCTD v4.0 Implementation
- New Recommendation to Swiss Medical Device Manufacturers
- JAZMP Q&A on Packaging
- MHRA Guidance on 3D Printing of Medical Devices
- Roszdravnadzor on Medical Software Examination
- EC on Medical Devices and PPE in the COVID-19 Context
- Russian Regulation on Medical Device Batch Registration
- EC Guidelines on COVID-19 In-Vitro Diagnostic Tests
- MHRA Guidance on Medicines and Medical Devices
- Team NB Position Paper on Dental Implants
- The UK Announces a New Bill on Medical Devices
- Assistive Technology Medical Device Regulations in the UK
- Brexit Transition Period: EMA and MHRA Notice
- MHRA Guidance on Grace Periods for Notified Bodies
- MHRA Guidance on Clinical Investigations
- Montenegro Law on Medical Devices 2019: an Overview
- MDCG Releases Guidance on Cybersecurity
- Switzerland and the EU on Mutual Recognition Agreements
- MDCG Explanatory Guidance on MDR Codes
- The MDCG’s Class II Medical Device Guidance
- EC MDCG Issues Notified Body Assessment Form
- MDCG Issued Guidance on Transitional Provisions
- EC Extends Application Period for Expert Panels
- UK Healthcare Sector Prepares for No-Deal Brexit
- Ireland’s Preparations for a No-Deal Brexit
- UK to Open Seven New Data Hubs
- German BfArM’s Warning on Medical Device OS Vulnerabilities
- Overview of IVDR
- European Commission Published Guidance on Vigilance System
- The EMA Published Draft Guidance on DDC Products.
- A Guide to Enter Your Medical Device in Italy
- Overview of Ireland’s Registration Process
- Guide to Enter Your Medical Device in Portugal
- New Recommendation to Swiss Medical Device Manufacturers
- A Guide to Enter Your Medical Device in Hungary
- Overview of the Medical Device Regulatory Market in Greece
- Medical Device Regulations in Germany
- Things You Should Know Before Registering Your Medical Devices In France
- Our Guide to Registering Medical Devices in Croatia
- Overview of Medical Device Regulations in Bulgaria
- How to Register Medical Devices in Russia
- An Overview of Medical Device Regulations in Belgium
- An Overview of Medical Device Regulations in Austria
- MEB and Swissmedic Agree On Greater Collaboration
- Swissmedic Moves Certificate Application Processes to Online Platform
- EMA Updates Brexit Guidance Documents for Drugmakers
- The EU’s GDPR is here. Here’s what your healthcare organization needs to know.
- New References Published for EU’s Harmonized OJEU standarts
- Amsterdam Announced as the New Home for EMA
- The Impacts of Brexit on Healthcare
- New Medical Device Regulation in Russia
- New Drug and Device Regulatory Requirements for Eurasian EEU Countries
- Comparing U.S. and E.U. Biosimilar Regulations
- Get to Know: CIS Regulatory Authorities
- Advancements in New EU Medical Device Legislation
+FDA
- FDA Guidance on 510(k) and Review Clock: Overview
- FDA Guidelines on Medical Device Classification: Overview
- FDA Guidance on Viral Mutations: Antigen Diagnostic Tests
- FDA Guidance on PBM Devices: Wireless Technology, Thermal and Eye Safety
- FDA Policy on Viral Mutations: Molecular Diagnostic Tests
- FDA Guidance on Photobiomodulation Devices: Usability and EMC
- FDA Guidance on Viral Mutations: General Principles
- FDA Draft Guidance on the Content of Human Factors Information: Recommendations
- FDA Draft Guidance on VMSR Program: Scope and General Conditions
- FDA Draft Guidance on PBM Devices: Predicate Comparison and Labeling
- FDA Draft Guidance on PBM Devices: Reprocessing, Biocompatibility and Software
- FDA Policy on Viral Mutations: Overview
- FDA Revised Policy for COVID Tests: Key Points
- FDA Draft Guidance on the Content of Human Factors Information: Recommendations
- FDA Guidance on Content of Human Factors Information: Overview
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Investigation Plan and Definitions
- FDA Guidance on Sustaining the Quality of Clinical Studies: Study Analysis and Changes to Pivotal Studies
- FDA Draft Guidance on Denying or Limiting an Inspection
- FDA Guidance on Sustaining the Quality of Clinical Studies: Study Conduct
- FDA Draft Guidance on Delaying an Inspection: Reasonable and Unreasonable Delays
- FDA Draft Guidance on VMSR Program: Supplemental Reports and Summary Reporting
- FDA Draft Guidance on Inspection Delays: Overview
- FDA Guidance on VMSR Program: Special Conditions
- FDA Draft Guidance on VMSR Program: Scope and General Conditions
- FDA Draft Guidance on Human Factors Information: Risk-Based Approach
- FDA Draft Guidance on VMSR Program: Product Code Eligibility
- FDA Draft Guidance on VMSR Program: Principles and Eligibility Determination
- FDA Draft Guidance on Voluntary Malfunction Summary Reporting Program: Overview
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Sustaining the Quality of Clinical Studies
- FDA Guidance on Post-Approval Studies: Failure to Comply and Disclosure
- FDA Guidance on Diagnostic Clinical Performance Studies: Preventing Bias
- FDA Guidance on Post-Approval Studies: Status Categories
- FDA Guidance on Diagnostic Clinical Performance Studies: Population, Planning, Selection
- FDA Guidance on Post-Approval Studies: Evaluation
- FDA Guidance on Diagnostic Clinical Performance Studies: Key Points
- FDA Guidance on Referencing the Definition of “Device”: Overview
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Placebo Effect
- FDA Guidance on Ethical Considerations for Clinical Investigations Involving Children: Study Procedures and Summary
- FDA Guidance on Design Considerations for Clinical Outcome Studies: Controls
- FDA Guidance on Ethical Considerations for Clinical Investigations Involving Children: Design Considerations
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Intervention Assignment and Masking
- FDA Guidance on Ethical Considerations for Clinical Investigations Involving Children: Parental Permission and Supporting Data
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Endpoints
- FDA Guidance on Ethical Considerations for Clinical Investigations Involving Children: Direct Benefit
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Stratification and Site Selection
- FDA Guidance on Ethical Considerations for Clinical Investigations with Children Involved: Principles and Risk Categories
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Study Objectives and Selection
- FDA Guidance on Ethical Considerations for Clinical Investigations: Overview
- FDA Guidance on Design Considerations of Pivotal Clinical Investigations: General Principles, Bias and Variability
- FDA Guidance on Distinguishing Medical Device Recalls from Enhancements: Identifying a Recall
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Types of Medical Devices
- FDA Guidance on Distinguishing Medical Device Recalls from Enhancements: Key Concepts and Definitions
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Evidence-Related Matters
- FDA Guidance on Distinguishing Recalls From Enhancements: Overview
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Evidence
- FDA Guidance on Abbreviated 510(k) Program: Overview
- FDA Guidance on Design Considerations for Pivotal Clinical Investigations: Overview
- FDA Guidance on Production Software Assurance: Record-Keeping
- FDA on Low-Risk Devices: Determining the Risk
- Philippines Guidance on Abridged Processing of Applications: Overview
- FDA Guidance on Production Software Assurance: Appropriate Assurance Activities
- FDA Guidance on Low-Risk Devices: Overview
- FDA Guidance on Production Software Assurance: Risk-Based Approach
- FDA Guidance on the Least Burdensome Approach: Timing
- FDA Guidance on Computer Software Assurance: Determination
- FDA Guidance on the Least Burdensome Approach: Smart Regulation and Global Harmonization
- FDA Guidance on Monkeypox Tests: Specific Aspects
- FDA Guidance on the Least Burdensome Approach: Streamlining the Process
- FDA Guidance on Monkeypox Tests: Modifications, Notification Content, and Reporting
- FDA Guidance on the Least Burdensome Approach: Clinical Studies and Benefit-Risk Assessments
- FDA Guidance on Monkeypox Tests: Initial Authorization
- FDA Guidance on Computer Software Assurance: Overview
- FDA Guidance on the Least Burdensome Approach: The Minimum Information Necessary
- FDA Guidance on Monkeypox Tests: Overview
- FDA Guidance on SR and NSR Studies: FDA Responsibilities and Examples
- FDA Guidance on the Least Burdensome Approach: Guiding Principles
- FDA Guidance on SR and NSR Studies: IRBs’ Responsibilities
- FDA Guidance on Least Burdensome Provisions: Overview
- FDA Guidance on Significant Risk and Nonsignificant Risk Medical Device Studies: Overview
- FDA Guidance on Manufacturing Information in PMAs: Specific Aspects
- FDA Guidance on Medical Device Patient Labeling: Pretesting
- FDA Guidance on Manufacturing Information and Operations in PMAs: Review Process
- FDA Guidance on Medical Device Patient Labeling: Warnings and Precautions
- FDA Guidance on Review and Inspection of PMA: Overview
- FDA Guidance on Patient Labeling: Appearance of Text and Graphics
- FDA Guidance on IDEs for NHHDs: Training and Labeling in Investigational Plan
- FDA Guidance on Medical Device Patient Labeling: Readability
- FDA Guidance on NHHD Systems: Investigation Plan
- FDA Guidance on Medical Device Patient Labeling: Troubleshooting and Additional Information
- FDA Guidance on IDEs for NHHDs: Reports of Prior Investigation
- FDA Guidance on Medical Device Patient Labeling: Operational Information
- FDA Guidance on NHHD: Physical and Electronic Characteristics; Functions and Features
- FDA Guidance on Medical Device Patient Labeling: Descriptive Information
- FDA Guidance on IDEs for Nocturnal Home Hemodialysis: Overview
- FDA Guidance on Medical Device Patient Labeling: Specific Aspects
- FDA Guidance on PMA Supplement Decision-Making Process: Changes to Manufacturing Site and Periodic Reports
- FDA Guidance on Medical Device Patient Labeling: Overview
- FDA Guidance on PMA Decision-Making Process: 30-Day Supplement
- FDA Guidance on PMA Decision-Making Process: Special PMA Supplement
- FDA Guidance on Home Use Devices: Postmarket Considerations
- FDA Guidance on PMA Supplement Decision-Making Process: Real-Time Supplement
- FDA Guidance on Home Use Devices: Labeling
- FDA Guidance on PMA Supplement Decision-Making Process: 180-Day Supplement
- FDA Guidance on Home Use Devices: Human Factors
- FDA Guidance on PMA Supplement Decision-Making Process: Panel-Track Supplement
- FDA Guidance on Home Use Devices: Electrical Issues
- FDA Guidance on the PMA Supplement Decision-Making Process: Traditional PMA
- FDA Guidance on Home Use Devices: Design Considerations
- FDA Guidance on the PMA Supplement Decision-Making Process: Overview
- FDA Guidance on Home Use Devices: User Considerations
- FDA Guidance on Home Use Devices: Environmental Considerations
- FDA Guidance on Manufacturing Site Changes Supplements: Submission Content
- FDA Guidance on Home Use Devices: Overview
- FDA Guidance on Manufacturing Site Change Supplements: Submission Type Determination
- FDA Guidance on Manufacturing Site Change Supplements: Overview
- FDA Guidance on Quantitative Imaging: Specific Aspects
- FDA Guidance on Quantitative Imaging: Overview
- FDA Guidance on Tissue Containment Systems: Non-Clinical Performance Testing
- FDA Guidance on Quantitative Imaging: Overview
- FDA Draft Guidance on Tissue Containment Systems: Overview
- FDA on Electromagnetic Compatibility of Medical Devices: Modifications and Labeling
- FDA on Heater-Cooler Devices
- FDA Guidance on Electromagnetic Compatibility: Testing, Allowances, and Deviations
- FDA Guidance on Sterility Information: Overview
- FDA Guidance on Electromagnetic Compatibility: Standards and Testing
- FDA Guidance on Orthopedic Fracture Fixation Plates: Testing a Validation
- FDA Guidance on Electromagnetic Compatibility of Medical Devices: Overview
- FDA Guidance on Orthopedic Fracture Fixation Plates: Overview
- FDA Guidance on Quality System Information: Specific Aspects
- FDA Q&A on eMDR: Overview
- FDA Guidance on VIP: Modified Submission Formats
- FDA Guidance on Voluntary Improvement Program: Flow and Activities
- FDA Guidance on Fostering Medical Device Improvement: Key Points
- FDA on Clinical Studies for Glycemic Control Devices: Specific Aspects
- FDA Guidance on a Safer Technologies Program: Mechanisms for Feedback
- FDA Guidance on Clinical Studies for Glycemic Control Devices: Duration and Inclusion/Exclusion Criteria
- FDA Guidance on STeP: Additional Considerations for Entrance Review
- FDA Guidance on Clinical Studies for Glycemic Control Devices: Overview
- FDA Guidance on Safer Technologies Program: Eligibility Factors
- FDA Guidance on Facet Screw Systems
- FDA Guidance on Safer Technologies Program: Principles
- FDA Guidance on Quality System Information: Manufacturing Details
- FDA Safer Technologies Program: Overview
- FDA Guidance on Quality System Information: Design Control Information
- FDA Guidance on Quality System Information: Overview
- FDA Guidance on Substantial Equivalence: Requests for Performance Data
- FDA Guidance on IDEs for Early Feasibility Studies: Specific Aspects
- FDA Guidance on Substantial Equivalence: Technological Characteristics
- FDA Guidance on IDEs for Early Feasibility Studies: Iterations
- FDA Guidance on Substantial Equivalence: Intended Use
- FDA Guidance on Investigational Device Exemptions: Investigation Plan
- FDA Guidance on Human Factors: Specific Aspects
- FDA Guidance on IDEs For Early Feasibility Studies: Specific Aspects of Prior Investigations
- FDA Guidance on IDEs For Early Feasibility Studies: Device Evaluation Strategy
- FDA Guidance on Human Factors Validation Testing: Analysis and Residual Risk
- FDA Guidance on IDEs for Early Feasibility Studies: Report of Prior Investigations
- FDA Guidance on Simulated-Use Human Factors Validation Testing: Data Collection
- FDA Guidance on Early Feasibility Study IDEs: Key Points
- FDA Guidance on Human Factors Validation Testing: Simulated Use and Participants
- FDA Guidance on Elimination of Use-Related Hazards and Human Factors Validation Testing
- FDA Guidance on IDEs for Early Feasibility Studies: an Overview
- FDA Guidance on Human Factors and Usability Engineering: Formative Evaluation
- FDA Guidance on Evaluation of Substantial Equivalence: Predicate Devices
- FDA Guidance on Human Factors and Usability Engineering: Analytical and Heuristic Approaches
- FDA Guidance on Substantial Equivalence: Categories and Decision-Making Flowchart
- FDA Guidance on Human Factors and Usability Engineering: Critical Tasks Assessment
- FDA Guidance on Substantial Equivalence in Premarket Notifications: Review Standard
- FDA Guidance on Human Factors and Usability Engineering: Users, Environment, Interface
- FDA Guidance on Human Factors and Usability Engineering: Overview
- FDA Guidance on Additive Manufactured Medical Devices: Material Characterization
- FDA Guidance on PRO Instruments: Best Practices
- FDA Guidance on Patient-Reported Outcome Instruments: Key Principles in Brief
- FDA Guidance on Additive Manufactured Medical Devices: Testing Considerations
- FDA Guidance on Patient Engagement: Policy in Detail
- FDA Guidance on Patient Engagement: Introduction
- FDA Guidance on Additive Manufactured Medical Devices: Material Controls, Post-Processing, and Validation
- FDA Guidance on Additive Manufactured Medical Devices: Software-Related Aspects
- FDA Guidance on Evaluating Substantial Equivalence in Premarket Notifications: Overview
- FDA Guidance on Medical Device Reporting: Additional Clarifications
- FDA Guidance on Additive Manufactured Medical Devices: Design Process in Brief
- FDA Guidance on Additive Manufactured Medical Devices: Definitions and Overview
- FDA Guidance on Medical Device Reporting: Completion of the Report
- FDA Guidance on Medical Device Reporting: Specific Cases
- FDA Guidance on Software Validation: Automated Process Equipment and Quality System Software
- FDA Guidance on Additive Manufactured Medical Devices: Basics
- FDA Guidance on Software Validation: User Site Testing and Maintenance
- FDA Guidance on GUDID Requirements for Certain Devices: Revised Policy
- FDA Guidance on the Content of Premarket Submissions for Device Software Functions: Additional Aspects
- FDA Guidance on General Principles of Software Validation: Changes and Testing Levels
- FDA Guidance on GUDID: Account Roles
- FDA Guidance on Content of Premarket Submissions for Device Software Functions: Development and Testing
- FDA Guidance on the Safety and Performance Based Pathway: Policy in Detail
- FDA Guidance on the Content of Premarket Submission for Device Software Functions: Documents in Detail
- FDA Guidance on Safety and Performance Based Pathway
- FDA Draft Guidance on Content of Premarket Submissions for Device Software Functions: Introduction
- FDA Guidance on Premarket Submissions for Device Software Functions: Definitions and Documentation
- FDA Guidance on GUDID: Modules
- FDA Guidance on Software Validation Activities: Testing by the Developer
- FDA Guidance on GUDID: Device Identifier (DI) Record
- FDA Guidance on Software Validation Tasks: Design and Coding
- FDA Guidance on De Novo Classification Requests and Review Clock: Requester’s Actions
- FDA Guidance on Surgical Staplers and Staples – Technical Characteristics
- FDA Guidance on De Novo Requests: Review Clock and Goals
- FDA Guidance on Surgical Staplers and Staples for Internal Use – Labelling Recommendations
- FDA Guidance on Software Validation: Activities and Tasks in Brief
- FDA Guidance on GUDID Account: Key Concepts
- FDA Guidance on De Novo Requests and Effect on FDA Review Clock and Goals: FDA Actions
- FDA Guidance on GUDID: Key Points
- FDA Draft Guidance on Hearing Aid Devices
- FDA Guidance on Postmarket Management of Cybersecurity: Additional Aspects
- FDA Guidance on Principles of Software Validation
- FDA Guidance on Remanufacturing Medical Devices: Specific Aspects
- FDA Guidance on Cybersecurity: Remediating and Reporting Cybersecurity Vulnerabilities
- FDA Guidance on Software Validation: Context
- FDA Guidance on Testing and Labeling Medical Devices for Safety in the Magnetic Resonance Environment: Labeling
- FDA Guidance on Remanufacturing Medical Devices: Defining the Scope
- FDA Guidance on Design Control: Design History File
- FDA on Medical Device Cybersecurity Risk Management
- FDA Guidance on Software Contained in Medical Devices: Additional Aspects
- FDA Guidance on Design Control: Design Transfer and Design Changes
- FDA Guidance on BCI Devices: Clinical Performance Testing
- FDA Guidance on Reprocessing Medical Devices: Validation and FDA Review
- FDA on BCI Devices: Animal Testing
- FDA on Acceptance Review for De Novo Requests: the Checklist
- FDA Guidance on Acceptance Review for De Novo Classification Requests
- FDA Guidance on De Novo Framework: Review Process
- FDA Guidance on De Novo Process: Submissions
- FDA Guidance on De Novo Classification Process
- FDA Guidance on Infusion Pumps: Specific Aspects
- FDA Guidance on eSubmission – Current Template
- FDA Draft Guidance on Electronic Submission Template for Medical Device 510(k) Submissions
- FDA Guidance on Reprocessing Medical Devices: Validation of Cleaning
- FDA Guidance on Design Validation
- FDA Guidance on Infusion Pumps: Performance Testing
- FDA Guidance on Postmarket Management of Cybersecurity in Medical Devices: Definitions and General Principles
- FDA Guidance on Infusion Pumps: Hazard Analysis
- FDA Guidance on Design Control: Design Verification
- FDA Guidance on Reprocessing Medical Devices: Criterion 4 – 5 for Reprocessing Instructions
- FDA on Content of Premarket Submissions For Medical Device Software: Documents in Detail
- FDA Draft Guidance on Denture Base Resins
- FDA Guidance on Infusion Pumps: Safety Assurance Cases
- FDA Guidance on Design Control: Design Review
- FDA Guidance on Software Changes: Examples
- FDA Guidance on Mandatory Device Recalls and Corrections
- FDA Guidance on BCI Devices: Non-Clinical Bench Testing
- FDA Guidance on Reprocessing Medical Devices: Criteria 1-3 for Reprocessing Instructions
- FDA Guidance on Medical Device Reporting: Specific Issues
- FDA Guidance on Premarket Submissions for Software Contained in Medical Devices: Documentation
- FDA Guidance on Software Validation: Terminology
- FDA Guidance on Medical Device Reporting: Written Procedures, Record-keeping and Public Disclosure
- FDA Guidance on Recalls: Additional Aspects
- FDA Guidance on Design Control: Design Output
- FDA Guidance on Regulatory Requirements for Device Software Functions
- FDA Guidance on Infusion Pumps: Device Description
- FDA Guidance on Development of Medical Device Labeling
- FDA on Medical Device Reporting: Specific Aspects
- FDA Guidance on BCI Devices: Specific Aspects
- FDA on Labeling For Radiation-Emitting Devices and Light-Emitting Products
- FDA Issues Final Rule Regarding “Intended Use”
- FDA Guidance on Good Manufacturing Practice Labeling Requirements
- FDA on MDR: Manufacturer’s Reporting Requirements in Detail
- FDA on Early Collaboration Meetings: Determination Meetings
- FDA Guidance on Recall Strategy: Development and Execution
- FDA Guidance on Design Control: Design Input
- FDA on Software Changes: Additional Factors
- FDA Policy on Software Functions
- FDA Guidance on Labeling for In Vitro Diagnostic Devices
- FDA Guidance on Manufacturer Reporting Requirements: Awareness and Submission
- FDA on Reusable Medical Devices and Reprocessing
- FDA on Implanted Brain-Computer Interface Devices: Software and Human Factor
- FDA Guidance on Infusion Pumps: Overview
- FDA Guidance on General Device Labeling
- FDA on Electronic Source Data in Clinical Investigations
- FDA Guidance on Recalls and Enhancements
- FDA Guidance on Recalls
- FDA on Postmarket Management of Cybersecurity in Medical Devices
- FDA Guidance on Design Control Basics
- FDA on Cybersecurity Practices for Servicing Medical Devices
- FDA Guidance on Unique Device Identification System
- FDA Guidance on Requests for Information
- FDA on General Principles of Labeling for Medical Devices
- FDA on Manufacturer Reporting Requirements
- FDA Guidance on Reprocessing Medical Devices in Health Care Settings
- FDA Guidance on Early Collaboration Meetings
- FDA Guidance on Electronic Medical Device Reporting (eMDR)
- FDA Safety Communication on Flexible Bronchoscopes
- FDA Guidance on Medical Device Data Systems and Image Devices
- FDA on Mobile Medical Applications: Basics
- FDA on General Principles of Software Validation
- FDA: How to Tell When a Software Change Requires a New 510(K)
- FDA Draft Guidance on Remanufacturing of Medical Devices
- FDA Guidance on Assessment of Radiofrequency-Induced Heating
- FDA on Cybersecurity for Networked Medical Devices Containing OTS Software
- FDA Guidance on Off-The-Shelf Software Use in Medical Devices
- FDA Premarket Submissions for Software Contained in Medical Devices
- FDA on Cybersecurity-related Content of Premarket Submissions
- FDA Guidance on Magnetic Resonance Diagnostic Devices
- FDA Guidance on Reporting of Computational Modeling Studies
- FDA Guidance on Premarket and Postmarket Data Collection
- FDA Guidance on Post-Approval Studies
- FDA on Postmarket Surveillance Under Section 522 of the FD&C Act
- FDA on Investigational Device Exemptions for Early Feasibility Studies
- FDA Guidance on Non-Clinical Bench Performance Testing Information
- FDA Guidance on 510(k) for Software Changes
- FDA Guidance on Feasibility and Early Feasibility Clinical Studies
- FDA Guidance on Implanted Brain-Computer Interface Devices
- FDA Guidance on Testing and Labelling Medical Devices for Safety in the Magnetic Resonance Environment
- FDA Guidance on 510(k) for Changes to Existing Devices
- FDA on Evaluation of Automated Endoscope Reprocessors
- FDA eSTAR Pilot Program
- FDA Medical Device Classification Update
- FDA Guidance on Acceptance and Filing Reviews for PMAs
- FDA Notice on Regulatory Flexibilities and Exemptions
- FDA on 510(k) Acceptability Criteria
- FDA Guidance on Preparing a Pre-Request for Designation
- FDA Guidance on Writing a Request for Designation
- FDA Guidance on Types of Communication
- FDA Guidance on eCopy Program for Medical Device Submissions
- FDA Guidance on Benefit-Risk Factors in Premarket Notifications (510(k))
- FDA on Significant and Nonsignificant Risk Medical Device Studies
- FDA Guidance on Q-Submission Program
- FDA Policy on Viral Mutations and COVID-19 Tests
- FDA Guidance on Patient-Reported Outcome Measures
- FDA Guidance on Intravascular Stents and Associated Delivery Systems
- CDRH on the Patient Science and Engagement Program
- FDA Breakthrough Devices Program: Request, Review, and Features
- FDA Guidance on Safer Technologies Program for Medical Devices
- FDA on Mouse Embryo Assay for Assisted Reproduction Technology Devices
- FDA Breakthrough Devices Program: General Overview
- FDA Guidance on Coagulation Systems for Measurement of Viscoelastic Properties
- FDA Action Plan for AI/ML-Based SaMD
- FDA Guidance on MDSAP Audit Approach
- FDA on Product Labeling for Laparoscopic Power Morcellators
- FDA Criteria for Spinal Plating Systems and Orthopedic Non-Spinal Metallic Bone Screws and Washers
- FDA Virtual Town Hall on COVID-19 Tests
- FDA Proposed Framework for Modifications to AI/ML-Based SaMD
- FDA on Requesting Feedback on Combination Products
- FDA Enforcement Policy for Bioburden Reduction Systems
- FDA on Radio Frequency Wireless Technology in Medical Devices
- FDA on Benefit-Risk Factors for Medical Devices: Key Points
- FDA Guidance on Electromagnetic Compatibility
- FDA Guidance on Certificates of Confidentiality
- FDA Guidance of Micro-Needling Products
- FDA: Requesting a Review of Decision Not to Issue an Export Certificate
- FDA on Exporting Medical Devices
- FDA ASCA Pilot Program in Detail: Development and Roles
- FDA Revised Policy for Remote Monitoring Devices
- FDA: Recognition and Withdrawal of Voluntary Consensus Standards
- FDA Communication Paper on Cybersecurity Vulnerabilities
- FDA Guidance on Medical Devices Containing Nitinol
- FDA Draft Guidance on Biocompatibility of Certain Devices
- FDA Policy for Modifications to Molecular Influenza and RSV Tests
- FDA: Blood Glucose Monitoring Systems for Prescription Point-of-Care Use
- FDA on Biocompatibility Testing of Devices Under ASCA Pilot
- FDA Guidance on Self-Monitoring Blood Glucose Test Systems
- FDA: Basic Safety and Essential Performance of Medical Electrical Equipment
- Taiwan Technical Guidelines on Medical Device Software
- FDA: Accreditation Scheme for Conformity Assessment Pilot Program
- FDA Medical Software Pre-Cert Pilot Program
- FDA Improves the Electronic Medical Device Reporting System
- FDA Guidance on International Standard ISO 10993-1
- FDA: Annual Reports for Approved PMA
- FDA Voluntary Consensus Standards
- FDA: Patient-Reported Outcome Instruments for Use in Evaluation
- FDA to Reclassify Non-Invasive Bone Growth Stimulators
- FDA Guidance on Cutaneous Electrodes for Recording Purposes
- FDA Guidance on the Safety and Performance Based Pathway
- FDA FAQ on Importing, Registration and Listing Medical Devices
- FDA Pilot Program for RFD and Pre-RFD Electronic Submissions
- FDA Amends Medical Device User Fees
- FDA Exemption for Class II Medical Devices
- FDA Guidance on Clinical Investigations for Prostate Tissue Ablation Devices
- FDA Guidance on Electronic 745A(b) Submissions for Medical Devices
- FDA Guidance on BHP Treatment Medical Devices
- SFDA: Listing and Marketing Authorization Requirements
- FDA Policy on Unique Device Identification
- FDA Guidance on Medical Device Establishment Inspections
- FDA Approves First Medical Device Development Tools
- EC Guidelines on Manufacturer Incident Report Form
- FDA Template for Home Collection Kits
- FDA Guidance on Supplements for PMA and HDE Submissions
- Infusion Pumps: FDA Emergency Use Authorization
- FDA: Final Guidance on 3P510K
- CDRH Guidance: Permanent Discontinuance or Interruption
- FDA Umbrella EUA for SARS-CoV-2 Antibody Tests
- FDA Guidance on Remote Digital Pathology Devices
- FDA Enforcement Policy for Telethermographic Systems
- FDA Guidance on Digital Health Devices
- FDA Enforcement Policy for Infusion Pumps and Thermometers
- FDA Guidance on Ventilators and Accessories
- FDA Policy on Remote Auditing Pilot Program
- Monitoring Devices: A New FDA Policy
- FDA Guidance on Clinical Trials During COVID-19 Pandemic
+IMDRF
- IMDRF Consultation Paper on Conformity Assessment Body Recognition
- IMDRF Proposed Framework for PMCF Studies
- IMDRF Framework for SaMD Quality Management System
- IMDRF Framework for SaMD Risk Categorization
- UK COVID-19 Tests Regulation
- IMDRF Framework on Software as a Medical Device
- IMDRF Guidance on Cybersecurity
- IMDRF Guidance on Requirements for CAB Assessors
- IMDRF Proposed Principles of IVD Classification
- Conformity Assessment Guidance from the IMDRF
+IVD
+Kazakhstan
- New Kazakhstan`s Medical Device Manufacturing Rules
- Kazakhstan: NDDA on Labeling Rules
- Kazakhstan’s NDDA on Medical Device Inspections
- Kazakhstan: Methods for Assessment of Optimal Technical Characteristics of Medical Devices
- Kazakhstan: New Medical Device Classification Rules
- Kazakhstan Implements Medical Device Advertising Rules
- Kazakhstan: New Rules on Recalls and Withdrawals
- Kazakhstan Adopts New Rules on Clinical Trials
+Malaysia
- MDA Draft Guidance on Medical Device Certificates: Information and Documentation
- MDA Draft Guidance on Applications of CFS, MC and CFS EO Certificates: Overview
- MDA Guidance on Establishment Licenses: Specific Aspects
- MDA Guidance on Establishment Licensing: Amendments
- MDA Guidance on Establishment Licensing: License Types and Application Process
- MDA Updated Guidance on Establishment Licensing: Overview
- MDA New Guidance on Re-Registration of Medical Devices: Overview
- MDA Guidance on Borderline Products
- MDA Guidance on Medical Device Advertisement
+MDCG
+MHRA
- MHRA Guidance on Registration of Medical Devices
- MHRA Draft Patient Involvement Strategy
- MHRA on Management and Organization of POCT
- MHRA Guidance on Medical Software and Applications
- MHRA on In-Vitro Diagnostic Point-of-Care Test Devices
- MHRA on Off-Label Use of Medical Devices
- MHRA on Custom-Made Medical Devices
- MHRA on Registration of Medical Device Manufacturers
- MHRA TPP for Point of Care SARS-CoV-2 Detection Tests
- UK: MHRA Notice On Safety-Critical Alerts
- MHRA Guidance on Field Safety Notices
+North America
- FDA Guidance on Third Party Review Program
- FDA Policy on Diagnostics Testing for COVID-19
- FDA Guidance on Third Party Review Program
- FDA Guidance on Electrosurgical Devices
- Document Submissions in Mexico: Guidelines
- Bone Anchor Devices: FDA Guidance
- Overview: FDA NESTcc Methods Framework
- FDA NESTcc Data Quality Framework
- FDA Guidance on CLIA Waiver Applications for IVDs
- Health Canada Implements eCTD for Clinical Trials
- FDA Guidance on Dual 510(k) and CLIA Waivers
- CDRH Introduces New Learning Modules
- FDA Final Guidance on Atherectomy Devices
- FDA Reports on ASCA Implementation Progress
- FDA Guidance on Arthroscopy Pump Tubing Sets
- FDA Guidance on Computer-Assisted Detection Devices
- Clinical Decision Supporting Software: Regulatory Framework
- FDA Guidance on Application Requirements for Devices
- FDA Publishes Order Regarding 510(k) Exemption
- FDA Guidance on Communication Procedures
- FDA Issues Guidance on Testing Information
- FDA Introduces Electronic Medical Device Submission System
- The FDA’s New Medical Device Regulatory Framework
- FDA on Pediatric Medical Device Submission Requirements
- Health Canada Creates the Medical Device Directorate
- CDRH Implements Surveys on Medical Device Shortages
- Recent FDA Guidance on Export Certificates
- The FDA Modifies List of Medical Device Registration Standards
- The FDA Clarifies Requirements on Conformity Assessment
- FDA Guidance on Citizen Petitions Against Applications
- FDA Releases Four Finalized Guidances on 510(k) Submissions
- FDA’s CDRA Warns About Cybersecurity
- FDA Updated Guidance on De Novo Requests
- FDA Finalized Guidance on HDE Program
- FDA’s Guidance on Placebos
- FDA Shifts from QSR and ISO 13485
- FDA Wants To Improve Risk-Based Monitoring In Clinical Trials
- Health Canada Opens Public Consultation About Promotional Ads
- FDA’s Speed Review of Generic Opioid Overdose Anecdotes
- Canada’s Cybersecurity Requirements for Medical Devices
- FDA’s 2018 Cybersecurity Guidance Overview
- FDA Announces Medical Device Reporting Changes
- The Current Regulations of Mobile Health
- Health Canada Increases Regulatory Prices of Medical Devices
- Future of AI/ML-Based SaMD and the Application
- Software Pre-certification Pilot Program (Pre-Cert)
- FDA’s Temporary Framework of AI/ML-based SaMD (part 2)
- FDA’s Temporary Framework of AI/ML-based SaMD (part 1)
- FDA Proposes a Framework to Support Innovative Medical Software
- FDA Released Document on Unapproved Diabetes Management Devices
- RMAT Designation: The Requirements and Benefits
- Health Canada Guidance: Medical Devices and 3-D Printing
- FDA Announced Changes to Reporting Requirements
- FDA Guidance on Medical Devices with Quantitative Imaging
- FDA Safety Communication on Unapproved Medical Devices
- FDA Guidance on Medical Devices Containing Materials Derived from Animal Sources
- FDA Issued a Safety Communication on Cybersecurity Vulnerabilities
- How Will Medical Devices Be Impacted by USMCA?
- FDA to Resume Inspection Activities Amid Government Shutdown
- Health Canada Issues New Plan for Medical Devices
- Important Things to Know Before Registering Your Medical Device in Canada
- An Overview of Medical Device Regulations in the US
- NESTcc Chooses 8 RWE Test Cases to Evaluate Medical Device Performance
- Safe Medical Devices Act (SMDA)
- FDA to Transition to ISO 13485
- The Lowdown on Humanitarian Device Exemption
- What Is FDA Priority Review?
- What Is Fast Track Designation?
- FDA Finalizes Guidance on IRB Written Procedures
- First Non-Opioid Treatment for Opioid Withdrawal Symptoms Approved by FDA
- How the United States Stacks Up Against its Global Competitors in Drug Approvals
- Organizations Push for Change of Clinical Diagnostics Regulations for FDA
- A Time of Change for Marijuana Legalization
- FDA Releases First Ever Medical Device 3D-Printing Guidance
- What Is the Best Way to Identify Your Predicate Device?
- What Do the FDA’s New 510(k) Exemptions Mean for You?
- 3 Things You Need to Know About the FDA’s Digital Health Innovation Plan
- How Will Trump’s Tax Plan Impact Pharmaceutical Companies?
- Cures Act: Signed into law, now comes the hard part
- Can Your Patients Get You to Market Faster?
- Medical Device Tax: On the road to a full repeal?
- FDA Responds to Infusion Pump Controversies
- The Trump Administration’s FDA
- FDA Proposes to Withdraw Lannett and Mallinckrodt’s Concerta Bioequivalents
- RegTech: What It Is and Where It’s Headed
- How to Expedite Drug Approval
- The Cyber-Security of Medical Device Companies
- Clinton vs. Trump on Healthcare
- Reminder: UDI Implementation Due Date Approaching
- Laws Regulating Mobile Health Apps
- How to Maximize the Benefits of the Temporary Medical Device Tax Suspension
- Theranos FDA Scandal: A Closer Look
- Is Selling an Unauthorized Product Worth the Risk?
- Increased Fees for FDA Issued Medical Device Exportation Certificates
- 7 Frequently Asked Questions About Submitting a 510(k) or PMA Under FDA’s New Policies
- How the 4.2% Medical Device User Fee Increase Impacts You
- The Rapid Growth of the Mobile Health Industry in the U.S.
- Getting Mobile Medical Apps Ready for Primetime… and the FDA
- Research Shows Your Device Is Likely at Risk of Being Compromised
- What is a 510(k)?
- Sell Your Medical Device in the US in 3 Steps
- The FDA’s New Era of Test Regulation
+Peru
+RegDesk News/Info
- RegDesk’s AI-Powered Application Builder is revolutionizing regulatory affairs
- Why Most RIMS Platforms are Already Obsolete
- ANVISA Launches Notification Pathway for Low-Risk Medical Devices
- How to Avoid Pitfalls with Medical Device Distributors
- Best Practices for Partnering with a Medical Device Distributor in Your Target Market
- 4 Ways RegDesk Is Different from Emergo
- RegDesk Appoints Jixian Wang as CTO
- RegDesk Welcomes Hans Beinke, Former VP of Siemens Healthcare, to Its Advisory Board
- Brain Implants: What are they? Where are they going? How are they being Regulated?
- List of Countries without Formal Regulatory Approval Process
- RegDesk CEO, Priya Bhutani, Chosen as 1 of 15 women Changing the Face of Tech in Philadelphia
- Crowdsourcing for Pharma Companies
- All 3 Alliance of Women Entrepreneurs Fellows are DreamIt founders
- How Women Can Advance in the Male-Dominated STEM Industries
- 5 Tips for Sending Your Medical Device to a Sanctioned Country
- Global Medical Device Regulatory Insights
- Regulatory medical device Consultant Spotlight: Maria G.
- Why Having Local Pharma Consultants in Emerging Markets is Vital
- Success Story!
+Russia
- Roszdravnadzor on State Supervision: Control Activities
- Roszdravnadzor on State Supervision in the Sphere of Medical Devices
- Roszdravnadzor Publishes Regulation on Supervision on Medical Devices
- Russia`s New Medical Software Assessment Rules
- Russian Establishment License Regulation
- Russian Methodical Recommendations for Medical Software Assessment
- Medical Software Classification in Russia
+Saudi Arabia
- SFDA Guidance on AI/ML-based Medical Devices: QMS
- SFDA Guidance on AI/ML-based Medical Devices: Risk Management
- SFDA Guidance on AI/ML-based Medical Devices: Clinical Evaluation
- SFDA Guidance on POC Medical Devices: Specific Aspects and Procedures
- SFDA Guidance on AI- and ML-based Medical Devices: Key Elements of Clinical Evaluation
- SFDA Guidance on Point of Care Medical Devices: Overview
- SFDA Guidance on AI- and ML-based Medical Devices: Overview
- SFDA Guidance on Clinical Trials: Overview
- New SFDA Guidance on Innovative Medical Devices
- SFDA Guidance on Safe Use of Medical Devices: Radiation-Related Aspects
- SFDA Guidance on Safety for Use of Medical Devices: Overview
- Updated SFDA Guidance on Medical Devices Advertising
- SFDA Guidance on Approval Requirements for Medical Device Advertising
- SFDA Guidance on AI and Big Data-Based Medical Devices
- SFDA Guidance on Bundling/Grouping Criteria for Medical Devices
- SFDA Guidelines on Radioactive Materials
- SFDA: Importation Requirements of Devices Intended for Demonstration or Training Purposes Only
- SFDA Guidance On Marketing Authorization Procedures
- SFDA Guidance for Medical Device Importers and Distributors
- SFDA Guidance for Local Manufacturers
- SFDA Guidance for Medical Device Authorized Representatives
- SFDA Guidance for Overseas Manufacturers
- SFDA Guidance on Particle Accelerators
- SFDA on Quality Management System Auditing Organizations
- SFDA: Requirements for Medical Masks and Particulate Respirators
- SFDA Guidance on Requirements of Shipments
- SFDA Guidance on Electronic Instructions for Use Requirements
- SFDA Guidance on Field Safety Corrective Actions
- SFDA Draft Guidance for Combination Products Classification
- SFDA Guidance on Innovative Devices and Standards
- Saudi Arabia’s Platform for Medical Device Submissions
+South America
- Argentina Amends Medical Device Registration Procedures
- Argentina Updates Medical Device Registration Rules
- Our Guide For How to Register Medical Devices In Peru
- Things You Should Know Before Registering Your Medical Devices In Uruguay
- How to register medical devices in Paraguay
- Meet this Month’s #WebinarWednesday Speaker: Marcelo Antunes
- The Lowdown on Medical Device Regulations in Colombia
- How to Register Medical Devices in Mexico
- Our Guide for How to Register Medical Devices in Brazil
- An Overview of Medical Device Regulations in Argentina
- Brazil ANVISA to Wipe Out Existing Backlogs
- COFEPRIS Partners with CAAAREM to Promote Foreign Trade
- Brazil Proposes New Guideline for Importation
- A Sneak Peek into COFEPRIS’s Agenda for 2018
- ANVISA Introduces New Requirement for Clinical Investigation of Medical Devices
- Two New Regulatory Changes in Brazil
- 5 Medical Labeling Requirements In Brazil
- Medical Device Regulations ANMAT Argentina
+TGA
+UK
+Uncategorized
- RegDesk Presents 6 Tools to Get Your Medical Device to Market Faster
- Russian Regulation on State Supervision: Decisions, Appeals, and Criteria
- DGPA & DC Draft Guidance on High-Risk Medical Devices
- TGA Guidance on the Software for Use With COVID-19 Rapid Antigen Self-Tests: Introduction
- TGA Guidance on New Classification Rules for Software-Based Medical Devices (Diagnosing and Monitoring)
- MHRA Guidance on Clinical Investigations: Northern Ireland
- TGA on IVD Software
- SFDA Guidance on Labeling Requirements for Medical Devices
- Thailand Guidance for Medical Device Product Recalls
- FDA Guidance on Adverse Event Reporting During a Pandemic
- MDCG Guidance on Significant Changes
- TGA Timeframes for Regulation of Medical Devices
- Refurbished Medical Devices: Malaysia MDA Draft Guidance
- FDA Medical Device Exemptions and Registration Procedures
- Malaysia Issues Guidance on Orphaned Medical Devices
- Singapore Guidance on Field Safety Corrective Action
- Bahrain Medical Device Registration Guidelines
- Malaysia Issues New Medical Device Regulations
- Health Canada Issues Guidance on SaMD
- ISO Introduces New Risk Management Standard
- IMDRF Clinical Guidelines
- Difference Between ISO 13485: 2012 and 2016
